Strategic Partnerships Fry Laboratories has partnered with Beckman Coulter and BioID Genomics to develop rapid NGS diagnostics for SARS-CoV-2, including automation integration. This track record can be leveraged to pursue expanded co-development or distribution partnerships with instrument vendors and genomics players to scale joint workflows and market reach.

Niche Outsourcing Core capabilities in chronic inflammatory diseases and vector-borne diseases, with immunology, co-infection serology, biofilm detection, and sequencing. This positions Fry as an outsourced diagnostic partner for CROs, biopharma sponsors, and hospitals seeking specialized assays and flexible service levels.

NGS Capabilities Proven NGS assay development for SARS-CoV-2 and viral detection, with prior collaboration on rapid sequencing solutions. There is an opportunity to offer high-complexity sequencing services to diagnostic labs, academic institutions, and public health partners that require fast, accurate results.

Compliance Edge Participation in CAP and API quality control programs signals strong quality management and regulatory readiness. This can be a selling point for labs needing external QC, proficiency testing, or compliant testing partnerships in niche diagnostics.

Global-Ready A small, agile team with a worldwide testing capability enables flexible partnerships with larger networks, hospitals, and research institutions for rapid deployment of niche tests under white-label or contracted arrangements.